Pneumocystidomycetes

Fungal infections in the brain aren't just the stuff of movies – Africa grapples with a deadly epidemic

Retrieved on: 
星期四, 七月 13, 2023
Gaps, Review, Infection, Canker, Pressure, Human, Fungal infection, HIV, Atmosphere, Culture, Health care, Pneumocystis jirovecii, Fever, Cough, Immunodeficiency, Inflammation, Cryptococcosis, Brain, Research, COVID, Mucormycosis, Fungus, Facial, Thermoregulation, Death, Climate change, The Last of Us, Soil, Patient, Population, Risk, Cryptococcus neoformans, Pneumocystidomycetes, Immune system, Lower respiratory tract infection, Steroid, Diagnosis, Flucytosine, Health, Environment, Meningitis, Cryptococcus, Pneumonia, Skin, Disease, Truffle, Pharmaceutical industry, Vaccine

I am a neurobiologist who has been studying fungal infections of the brain for 10 years.

Key Points: 
  • I am a neurobiologist who has been studying fungal infections of the brain for 10 years.
  • I was part of a team that recently published a review discussing the emergence, and re-emergence, of fungal infections in Africa, especially in sub-Saharan Africa.
  • We conclude that Africa is suffering from a silent, but costly, epidemic of fungal infections.

What are fungal infections?

    • For the greater part of the history of humankind, fungal infections were never a threat to human health.
    • Even then, our immune systems are quite capable of fighting against fungal infections.
    • Africa accounts for 67% of the global burden of HIV, and opportunistic fungal diseases are on the rise.

Some examples

    • Today, sub-Saharan Africa contributes about 73% of all global cases and deaths resulting from the disease.
    • Cryptococcal meningitis is caused by the fungus Cryptococcus neoformans, which is found in soil and bird droppings.
    • It first leads to the development of a lung infection and later a fatal brain infection.
    • Cryptococcal meningitis is a leading cause of adult meningitis in sub-Saharan Africa and it’s associated with almost 20% of all AIDS-related deaths.

Growing burden

    • While these factors are not unique to Africa, the burden of fungal diseases and the number of people who succumb to them is much greater.
    • The COVID pandemic seems to have made the global fungal burden worse.
    • COVID-induced lung damage, high blood sugar, and the steroids often used to treat it are all predisposing factors to black fungus infection.

But don’t we have antifungal drugs?

    • With poorly funded and overburdened healthcare systems, many African countries are not well prepared to deal with fungal infections.
    • Additionally, some of the WHO-recommended antifungal drugs – such as flucytosine – are unavailable in most African countries.

Management strategies


    Fungal threats are adding pressure to overburdened health systems with a limited arsenal of treatment options. Healthcare professionals, scientific researchers, policymakers and governments must address the gaps in the diagnosis and management of fungal infections. This will help to improve capacity to deal with them.

Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
星期二, 十二月 20, 2022
Health, Pharmaceutical, Aspergillosis, Clinical trial, MDR, European Medicines Agency, QIDP, Breakthrough therapy, Research, III, News, NDA, Candida auris, Auris, Disease, Acquisition, Discovery, Infection, Drug of last resort, FDA, Therapy, Goodyear F2G Corsair, II, IV, Pharmaceutical industry, Aspergillus, Pneumocystidomycetes

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
  • The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D.

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Retrieved on: 
星期二, 十二月 14, 2021
Forward-looking statement, Hospital, Fluconazole, McNeil Consumer Healthcare, Aplastic anemia, FDA, NDA, QIDP, Mycosis, Restore, Physician, Securities Exchange Act of 1934, Drug Quality and Security Act, Candidiasis, Private Securities Litigation Reform Act, Transplant, COVID-19, Securities Act of 1933, Integrity, U.S. Securities and Exchange Commission, Safety, Posaconazole, Patient, Therapy, Security (finance), Pain management, Chronic myelogenous leukemia, Acute lymphoblastic leukemia, Lymphoma, Acute myeloid leukemia, New Shrimadhopur DFC Station, Webcast, Fungemia, Heart, Pharmaceutical industry, Respect, Pneumocystidomycetes, Aspergillus

SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.

Key Points: 
  • The trial is enrolling adults with underlying conditions including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome(s), lymphoma and aplastic anemia.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara has completed a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and is currently conducting a second Phase 3 clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).
  • Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Retrieved on: 
星期二, 十二月 14, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Forward-looking statement, Hospital, U.S. Securities and Exchange Commission, Fluconazole, McNeil Consumer Healthcare, Aplastic anemia, FDA, NDA, QIDP, Mycosis, Restore, Physician, Securities Exchange Act of 1934, Drug Quality and Security Act, Community, Candidiasis, Private Securities Litigation Reform Act, Food and Drug Administration, Transplant, European Commission, COVID-19, Epidemiology, Securities Act of 1933, Integrity, Safety, Posaconazole, Patient, Therapy, Security (finance), Pain management, Chronic myelogenous leukemia, Acute lymphoblastic leukemia, Lymphoma, Risk, Acute myeloid leukemia, DFC (cipher), Webcast, Fungemia, Heart, Pharmaceutical industry, Animal, Respect, Pneumocystidomycetes, Aspergillus

Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems.

Key Points: 
  • Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara has completed a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and is currently conducting a second Phase 3 clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).
  • Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.

Key Publication of Clinical Study Demonstrates Unyvero Lower Respiratory Tract (LRT) Panel is Likely to Alter Antibiotic Management of Significant Numbers of Patients Presenting with Suspected Pneumonia

Retrieved on: 
星期三, 九月 2, 2020
Fungi, Infectious diseases, Ascomycota, Organisms, Medical specialties, HIV/AIDS, Pneumocystis pneumonia, Pneumocystis jirovecii, Pneumocystidomycetes, Pathogenic fungus, PJP, Pneumonia

Antibiotics could have been optimized in 7.8% of patients through both de-escalation and expansion.

Key Points: 
  • Antibiotics could have been optimized in 7.8% of patients through both de-escalation and expansion.
  • Unyvero LRT BAL is the only FDA-cleared lower respiratory tract infection panel that includes Pneumocystis jirovecii, a causative agent of Pneumocystis pneumonia (PJP) and a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose.
  • This press release includes statements regarding the potential impact on antibiotic therapy regimen and clinical utility of the Unyvero LRT and LRT BAL cartridges.
  • We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.